Hypertrophic cardiomyopathy or hereditary hemochromatosis? (RCD code: III‑2B.3.o)

Katarzyna Holcman, Paweł Rubiś, Sylwia Wiśniowska‑Śmiałek, Agata Leśniak‑Sobelga, Marta Hlawaty, Magdalena Kostkiewicz, Piotr Podolec

Full Text:

PDF

Abstract


Hemochromatosis is a disease resulting from excessive deposition of iron in parenchymal tissues. The most common form of this disease is associated with the homozygous p.Cys282Tyr mutation of the HFE gene. It leads to multisystemic disease including iron overload cardiomyopathy. Heterozygotes usually do not express a hemochromatosis phenotype, however there are known cases of iron overload in this group of patients. We present a case of 48-year old man, with family history of hereditary hemochromatosis, p.Cys282Tyr mutation carrier, who was admitted to cardiology department due to persistent atrial fibrillation episode. Laboratory tests revealed transferrin serum iron saturation value of 47,8% with other parameters of iron metabolism within the reference range. Transthoracic echocardiographic study showed image consistent with hypertrophic cardiomyopathy. Sinus rhythm was successfully restored by synchronized electrical cardioversion. Based on cardiovascular magnetic resonance imaging cardiac iron overload cardiomyopathy was ruled out. He was discharged home in good general condition without symptoms. JRCD 2016; 3 (1): 24–27

Keywords


rare disease; iron overload cardiomyopathy; atrial fibrillation; echocardiography

References


Baranowski R, Bieganowska K, Kozłowski D, et al. Zalecenia dotyczące stosowania rozpoznań elektrokardiograficznych. Kardiol Pol 2010; 68 (supl. IV).

Bonow RO, Mann DL, Zipes DP, et al, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, PA: Elsevier Saunders; 2012.

Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328.

Niederau C, Fischer R, Pürschel A, et al. Longterm survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107.

Merryweather-Clarke AT, Pointon JJ, Shearman JD, et al. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275.

Alexander J, Kowdley KV. HFE-associated hereditary hemochromatosis. Genetics in Medicine 2009; 11: 307–313.

Bulaj ZJ, Griffen LM, Jorde LB, et al. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996; 335: 1799.

Aguilar-Martinez P, Grandchamp B, Cunat S, et al. Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants. Haematologica. 2011; 96: 507–514.

Brissot P, Moirand R, Jouanolle AM, et al. A genotypic study of 217 unrelated probands diagnosed as “genetic hemochromatosis” on “classical” phenotypic criteria. J Hepatol 1999; 30: 588–593.

Phatak PD, Ryan DH, Cappuccio J, et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 2002; 29: 41–47.

Crawford DH, Jazwinska EC, Cullen LM, et al. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998; 114: 1003–1008.

Eijkelkamp EJ, Yapp TR, Powell LW. HFE-associated hereditary hemochromatosis. Can J Gastroenterol 2000; 14: 121.

Hildebrand A, Bhagirath K, Ariyarajah V, et al. Myocardial siderosis due to hemochromatosis in an individual with hypertrophic cardiomyopathy. Can J Cardiol 2009; 25: e424–e425.

Podolec Piotr. Classification of Rare Cardiovascular Diseases (RCD Classification). JRCD 2013; 1: 49–60.

Gujja P, Rosing DR, Tripodi DJ, et al. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 2010; 56: 1001–1012.

Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation 2011; 124: 2253–2263.

Oudit GY, Sun H, Trivieri MG, et al. L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 2003; 9: 1187–1194.

O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014; 35: 2010–2020.

Elliott PM, Anastasakis A, Borger MA, et al. 2014 European Society of Cardiology Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014; 35: 2733–2779.




DOI: http://dx.doi.org/10.20418%2Fjrcd.vol3no1.264

Refbacks

  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
e-mail: rarediseases@szpitaljp2.krakow.pl
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659
e-mail: softq@softq.pl